BnR Summit 2026

Belt & Road Summit - Deal-Making 2026

9 – 15 Sept 2026 | Hong Kong, China (Hong Kong)

ProjectUpdated on 1 September 2026

Predicting Preterm Birth in Seconds

COO at EveryBaby

China (Hong Kong)

About

EveryBaby has developed a handheld medical device that assesses a woman's risk of spontaneous preterm birth starting from 14 weeks of pregnancy, delivering a result in seconds with no blood draw and no laboratory processing required. The device uses electrical impedance spectroscopy combined with machine learning to read the cervix directly at the point of care.

Our 449-woman clinical study in the UK is complete, and we currently hold conditional regulatory approval in Abu Dhabi. EveryBaby is headquartered in Hong Kong.

We are currently raising our seed round to advance further regulatory submissions, expand clinical validation into additional markets, and scale manufacturing ahead of commercial launch. We welcome conversations with investors focused on medtech, diagnostics, and women's health.

Project Location

  • China (Hong Kong)

Project Website

https://www.every-baby.com/

Project Format

  • Private Project

Go Global Project

  • Yes

ESG (Environmental, Social, and Governance)

  • Yes

Project Stage

  • Investment / Financing Discussion

Main Project Sector

  • Technology

Technology

  • Medical Technology

Investment Capital Required

  • 2,500,001 to 5,000,000 USD

Interested Format of Cooperation

  • Convertible Loan
  • Direct Equity Investment

Preferred Financing Model

  • Equity

Type(s) of Last Financing Round of the project (if Applicable)

  • Bootstrapping

Main Service(s) Required

  • Financial Services

Financial Services

  • Private Equity & Venture Capital

Organisation

EveryBaby

China (Hong Kong)

Similar opportunities